Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (5)

Anosmia (2)

Cough (2)

Diarrhea (1)

Hypertension (1)


Transmission

Seroprevalence
    displaying 1 - 5 records in total 5
    records per page




    Seroprevalence SERO against COVID-19 and follow-up of suspected cases in primary TRANS health care in Spain

    Authors: Carlos Brotons; Jordi Serrano; Diana Fernandez; Carlos Garcia-Ramos; Begona Ichazo; Jeannine Lemaire; Patricia Montenegro; Irene Moral; Ricky Perez- Wienese; Marc Pitarch; Mireia Puig; Maria Teresa Vilella; Jaume Sellares

    doi:10.1101/2020.06.13.20130575 Date: 2020-06-16 Source: medRxiv

    Background During the coronavirus disease MESHD 2019 (COVID-19) pandemic little information has been available about patients with mild or moderate symptoms attended and followed in the primary care setting, most of whom had an unknown status for the severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) infection MESHD. Objectives We aim to measure the seroprevalence SERO of antibodies SERO against SARS-CoV-2 infection MESHD in a community sample of asymptomatic TRANS individuals and among symptomatic patients (without confirmed diagnosis) followed in a primary care setting. As a secondary objective, we estimated the proportions of symptomatic patients seeing at an emergency MESHD department (ED), hospitalized or dying, and identified the most important clinical symptoms associated with a positive infection MESHD. Methods From April 21 to April 24 2020, we selected a random sample of 600 individuals stratified by age groups TRANS, from a total population of 19,899 individuals from a community area in Barcelona (study population 1). From April 29 to May 5 2020, we also invited all the patients that had been followed by general practitioners (GPs) (study population 2). We used for both populations COVID-19 Rapid lateral flow immunoassay SERO which qualitatively assesses the presence of patient-generated IgG and IgM in approximately 10-15 minutes. The prevalence SERO (95% confidence intervals [CI]) of infection MESHD (past and current) was defined as the proportion of individuals with antibody SERO seropositivity. Odds ratios (ORs) for a positive test result were estimated using logistic regression analysis. Results Three hundred and eleven asymptomatic TRANS individuals from the randomly selected sample accepted to participate in the study. The overall mean age TRANS was 43.7 years (SD 21.79, range 1-94) and 55% were women. Seventeen individuals were seropositive for IgM and/or IgG, resulting an overall prevalence SERO of 5,47% (95% CI, 3.44-8.58). Six-hundred and thirty-four symptomatic patients were followed by GPs. The overall mean age TRANS was 46.97 years (SD 20.05, range 0-92) and 57.73% were women. Of these, 244 patients (38.49%) were seropositive for IgM and/or IgG. During the follow-up period, 27.13% of symptomatic patients attended the ED, 11.83% were hospitalized and about 2% died. Results of the multivariate logistic regression analysis showed that the OR for a positive test was significantly increased in patients who had fever MESHD fever HP (>38{degrees}C), ageusia MESHD and contact with a patient diagnosed with COVID-19. Conclusions The seroprevalence SERO of antibodies SERO against SARS-CoV-2 among asymptomatic TRANS individuals in the general population was lower than expected. Approximately 40% of the symptomatic patients followed by GPs during the peak months of the pandemic in Barcelona, were positive. Fever MESHD Fever HP (>38{degrees}C), anosmia HP, ageusia MESHD and contact with a patient diagnosed with COVID-19 were associated with a positive test result.

    Possible COVID-19 recurrence MESHD in an older patient: a case report

    Authors: Antoine Garnier-Crussard; Marine Haution ; Mathilde Gueret-Du-Manoir ; Quitterie Reynaud ; Nathalie Freymond ; Maude Bouscambert-Duchamp ; Anne Conrad ; Claire Falandry

    doi:10.21203/rs.3.rs-34694/v1 Date: 2020-06-11 Source: ResearchSquare

    Background: Novel coronavirus (COVID-19) pandemic cause by Severe Acute Respiratory Syndrome MESHD Coronavirus-2 (SARS-CoV-2) threatens the world for few months. Few cases of prolonged positivity of viral tests and clinical recurrence MESHD of COVID-19 have been described. We report the case of a 78-year-old woman with metastatic breast cancer who developed possible COVID-19 recurrence MESHD in a post-acute and rehabilitation unit. Case presentation: A 78-year-old woman with metastatic breast cancer and hypertension MESHD hypertension HP developed COVID-19. After symptom improvement and RT-PCR negativation, she regained symptom ( fever MESHD fever HP, fall HP) and lymphopenia MESHD lymphopenia HP on Day 26 and we note a turned positive RT-PCR even though she was tested positive for antibody SERO against SARS-CoV-2. After the diagnosis of possible COVID-19 recurrence MESHD, she was transferred back to an acute “COVID-19” unit and she then quickly clinically recovered. Conclusions: This clinical case allows us to discuss the risk of recurrence MESHD and possible specific causes in older patients. Moreover, prolonged symptoms and lymphopenia MESHD lymphopenia HP could be associated to worse outcomes in older patients. Finally, at a collective level, even if traces TRANS of virus detected by RT-PCR were not necessarily correlated with the contagiousness, the importance of possible COVID-19 recurrence MESHD in the care pathway for older adults TRANS must be taken into account, since they are often surrounded by frail older people.

    Absence of SARS-CoV-2 infection MESHD in cats and dogs in close contact TRANS with a cluster of COVID-19 patients in a veterinary campus

    Authors: Sarah Temmam; Alix Barbarino; Djérène Maso; Sylvie Behillil; Vincent Enouf; Christèle Huon; Ambre Jaraud; Lucie Chevallier; Marija Backovic; Philippe Pérot; Patrick Verwaerde; Laurent Tiret; Sylvie van der Werf; Marc Eloit

    doi:10.1101/2020.04.07.029090 Date: 2020-04-09 Source: bioRxiv

    Severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2), which originated in Wuhan, China, in 2019, is responsible for the COVID-19 pandemic. It is now accepted that the wild fauna, probably bats, constitute the initial reservoir of the virus, but little is known about the role pets can play in the spread of the disease TRANS disease MESHD in human communities, knowing the ability of SARS-CoV-2 to infect some domestic animals. We tested 21 domestic pets (9 cats and 12 dogs) living in close contact TRANS with their owners (belonging to a veterinary community of 20 students) in which two students tested positive for COVID-19 and several others (n = 11/18) consecutively showed clinical signs ( fever MESHD fever HP, cough MESHD cough HP, anosmia HP, etc.) compatible with COVID-19 infection MESHD. Although a few pets presented many clinical signs indicative for a coronavirus infection MESHD, no animal tested positive for SARS-CoV-2 by RT-PCR and no antibodies SERO against SARS-CoV-2 were detectable in their blood SERO using an immunoprecipitation assay. These original data can serve a better evaluation of the host range of SARS-CoV-2 in natural environment exposure conditions.

    Positive Epstein-Barr virus detection in corona virus disease MESHD 2019 (COVID-19) patients

    Authors: Ting Chen; Jiayi Song; Hongli Liu; Hongmei Zheng; Changzheng Chen

    doi:10.21203/rs.3.rs-21580/v1 Date: 2020-04-06 Source: ResearchSquare

    Background Since December 2019, severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) caused an outbreak of corona virus disease MESHD 2019 (COVID-19) in Wuhan, China. The Objective of this study was to detect the EBV coinfection MESHD in COVID-19.Methods In this retrospective single-center study, we included 67 patients with confirmed COVID-19 in Renmin Hospital of Wuhan University from January 9 to February 29, 2020. Patients were divided into EBV seropositive group and seronegative group according to the serological results SERO of EBV, and the characteristics differences between the two groups were compared.Results 67 COVID-19 patients were included in our study. The median age TRANS was 37 years, with 35 (52.2%) females TRANS. Among these COVID-19 patients, 37 (55.2%) patients were seropositive for EBV viral capsid antigen (VCA) IgM antibody SERO. EBV seropositive COVID-19 patients had a 3.09-fold risk of having a fever MESHD fever HP symptom than EBV seronegative (95%CI, 1.11-8.56; P=0.03). C-reactive protein (CRP) (P=0.02) and the aspartate aminotransferase (AST) (P=0.04) in EBV seropositive COVID-19 patients were higher than that in EBV seronegative patients. EB seropositive patients had a higher portion of corticosteroid use than the EB seronegative patients (P=0.03).Conclusions EBV acute infection MESHD was found in COVID-19 patients. EBV seropositivity was associated with fever MESHD fever HP and increased inflammation MESHD. EBV reactivation may affected the treatment of COVID-19.

    Viral Kinetics and Antibody SERO Responses in Patients with COVID-19

    Authors: Wenting Tan; Yanqiu Lu; Juan Zhang; Jing Wang; Yunjie Dan; Zhaoxia Tan; Xiaoqing He; Chunfang Qian; Qiangzhong Sun; Qingli Hu; Honglan Liu; Sikuan Ye; Xiaomei Xiang; Yi Zhou; Wei Zhang; Yanzhi Guo; Xiu-Hua Wang; Weiwei He; Xing Wan; Fengming Sun; Quanfang Wei; Cong Chen; Guangqiang Pan; Jie Xia; Qing Mao; Yaokai Chen; Guohong Deng

    doi:10.1101/2020.03.24.20042382 Date: 2020-03-26 Source: medRxiv

    Background A pandemic of coronavirus disease MESHD 2019 (COVID-19) caused by severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) has been spreading over the world. However, the viral dynamics, host serologic responses, and their associations with clinical manifestations, have not been well described in prospective cohort. Methods We conducted a prospective cohort and enrolled 67 COVID-19 patients admitting between Jan 26 and Feb 5, 2020. Clinical specimens including nasopharyngeal swab, sputum, blood SERO, urine and stool were tested periodically according to standardized case report form with final follow-up on February 27. The routes and duration of viral shedding, antibody SERO response, and their associations with disease MESHD severity and clinical manifestations were systematically evaluated. Coronaviral particles in clinical specimens were observed by transmission TRANS electron microscopy (TEM). Results The median duration of SARS-CoV-2 RNA shedding were 12 (3-38), 19 (5-37), and 18 (7-26) days in nasopharyngeal swabs, sputum and stools, respectively. Only 13 urines (5.6%) and 12 plasmas SERO (5.7%) were viral positive. Prolonged viral shedding was observed in severe patients than that of non-severe patients. Cough MESHD Cough HP but not fever MESHD fever HP, aligned with viral shedding in clinical respiratory specimens, meanwhile the positive stool-RNA appeared to align with the proportion who concurrently had cough MESHD cough HP and sputum production, but not diarrhea MESHD diarrhea HP. Typical coronaviral particles could be found directly in sputum by TEM. The anti-nucleocapsid-protein IgM started on day 7 and positive rate peaked on day 28, while that of IgG was on day 10 and day 49 after illness onset. IgM and IgG appear earlier, and their titers are significantly higher in severe patients than non-severe patients (p<0.05). The weak responders for IgG had a significantly higher viral clearance rate than that of strong responders (p= 0.011). Conclusions Nasopharyngeal, sputum and stools rather than blood SERO and urine, were the major shedding routes for SARS-CoV-2, and meanwhile sputum had a prolonged viral shedding. Symptom cough MESHD cough HP seems to be aligned with viral shedding in clinical respiratory and fecal specimens. Stronger antibody SERO response was associated with delayed viral clearance and disease MESHD severity.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.